[go: up one dir, main page]

NO20075304L - Metode for avtagende forkalkning - Google Patents

Metode for avtagende forkalkning

Info

Publication number
NO20075304L
NO20075304L NO20075304A NO20075304A NO20075304L NO 20075304 L NO20075304 L NO 20075304L NO 20075304 A NO20075304 A NO 20075304A NO 20075304 A NO20075304 A NO 20075304A NO 20075304 L NO20075304 L NO 20075304L
Authority
NO
Norway
Prior art keywords
calcification
decreasing
emimetics
individuals
calcium
Prior art date
Application number
NO20075304A
Other languages
English (en)
Inventor
David Martin
Juan Mariano Portillo
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO20075304L publication Critical patent/NO20075304L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Den foreliggende oppfinnelsen angår fremgangsmåter for å behandle vaskulær forkalkning i individer ved å bruke kalsimimetika.
NO20075304A 2005-03-17 2007-10-17 Metode for avtagende forkalkning NO20075304L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66327005P 2005-03-17 2005-03-17
PCT/US2006/009683 WO2006102061A2 (en) 2005-03-17 2006-03-17 Methods of decreasing calcification

Publications (1)

Publication Number Publication Date
NO20075304L true NO20075304L (no) 2007-11-29

Family

ID=36588866

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075304A NO20075304L (no) 2005-03-17 2007-10-17 Metode for avtagende forkalkning

Country Status (15)

Country Link
US (1) US20060276534A1 (no)
EP (1) EP1858553A2 (no)
JP (1) JP2008533170A (no)
KR (1) KR20070116817A (no)
CN (1) CN101184508A (no)
AU (1) AU2006227429A1 (no)
BR (1) BRPI0609524A2 (no)
CA (1) CA2601669A1 (no)
CR (1) CR9439A (no)
EA (1) EA200701995A1 (no)
IL (1) IL185757A0 (no)
MX (1) MX2007011153A (no)
NO (1) NO20075304L (no)
WO (1) WO2006102061A2 (no)
ZA (1) ZA200707639B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007000982A (es) * 2005-05-23 2007-04-16 Teva Pharma Clorhidrato de cinacalcet amorfo y preparacion del mismo.
WO2007047969A2 (en) * 2005-10-21 2007-04-26 Amgen Inc. Methods of decreasing vascular calcification using il-1 inhibitors
US20070104799A1 (en) * 2005-11-09 2007-05-10 Shire International Licensing B.V. Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
CA2625299A1 (en) * 2005-11-22 2007-05-31 Teva Pharmaceutical Industries Ltd. Crystal forms of cinacalcet hci and processes for their preparation
US8415501B2 (en) * 2006-03-23 2013-04-09 Amgen, Inc. Methods and compositions for making and using polymorphs of cinacalcet
WO2007124465A2 (en) * 2006-04-20 2007-11-01 Amgen Inc. Stable emulsion formulations
DE602007003067D1 (de) * 2006-04-27 2009-12-17 Teva Pharma Verfahren zur herstellung einer cinacalcetbase
US7393967B2 (en) * 2006-04-27 2008-07-01 Teva Pharmaceutical Industries Ltd. Process for the preparation of cinacalcet base
US20090258949A1 (en) * 2006-06-27 2009-10-15 Johannes Ludescher Amorphous form of cinacalcet
US20080146845A1 (en) * 2006-11-20 2008-06-19 Boaz Gome Process for preparing Cinacalcet
CA2685962A1 (en) * 2007-05-08 2009-02-05 Burnham Institute For Medical Research Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification
WO2009025792A2 (en) * 2007-08-16 2009-02-26 Teva Pharmaceutical Industries Ltd. Crystalline forms cinacalcet fumarate and cinacalcet succinate and processes for preparation thereof
WO2013041205A1 (de) 2011-09-19 2013-03-28 Pyxirion Pharma Gmbh Neue therapeutische konzepte zur behandlung von gefässerkrankungen
US20130085121A1 (en) * 2011-09-30 2013-04-04 Jianguo Wang Pharmaceutical compositions comprising phosphate binder, calcium receptor-active compound and/or active vitamin d
US20140315809A1 (en) * 2011-11-10 2014-10-23 Kai Pharmaceuticals, Inc. Calcimimetics and methods for their use
US9539264B2 (en) * 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
EP3873490A1 (en) * 2018-10-25 2021-09-08 EirGen Pharma Ltd. Methods of treatment with mixed metal compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688938A (en) * 1991-08-23 1997-11-18 The Brigham & Women's Hospital, Inc. Calcium receptor-active molecules
US6313146B1 (en) * 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6001884A (en) * 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US5962314A (en) * 1993-02-23 1999-10-05 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
EP1275635A1 (en) * 1994-10-21 2003-01-15 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
DE69722934T2 (de) * 1996-05-01 2004-05-27 NPS Pharmaceuticals, Inc., Salt Lake City Verbindungen , die auf anorganische ionen-rezeptoren wirken
WO1998001417A1 (fr) * 1996-07-08 1998-01-15 Kirin Beer Kabushiki Kaisha Composes actifs comme recepteurs du calcium
TW483881B (en) * 1996-12-03 2002-04-21 Nps Pharma Inc Calcilytic compounds
WO2000021910A2 (en) * 1998-10-14 2000-04-20 Ortho-Mcneil Pharmaceutical, Inc. 1,2-disubstituted cyclopropanes
US6551990B2 (en) * 1998-12-07 2003-04-22 University Of Washington Methods of inhibiting ectopic calcification
NZ518334A (en) * 1999-10-19 2003-08-29 Genzyme Corp Direct compression polymer tablet core
US6908935B2 (en) * 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
US20050288377A1 (en) * 2004-06-14 2005-12-29 Cantor Thomas L Use of calcimimetic as an adynamic bone disease related treatment

Also Published As

Publication number Publication date
KR20070116817A (ko) 2007-12-11
MX2007011153A (es) 2007-12-12
EP1858553A2 (en) 2007-11-28
US20060276534A1 (en) 2006-12-07
CR9439A (es) 2007-11-23
IL185757A0 (en) 2008-01-06
CN101184508A (zh) 2008-05-21
AU2006227429A1 (en) 2006-09-28
WO2006102061A2 (en) 2006-09-28
JP2008533170A (ja) 2008-08-21
WO2006102061A3 (en) 2006-12-14
EA200701995A1 (ru) 2008-02-28
ZA200707639B (en) 2008-06-25
CA2601669A1 (en) 2006-09-28
BRPI0609524A2 (pt) 2011-10-18

Similar Documents

Publication Publication Date Title
NO20075304L (no) Metode for avtagende forkalkning
WO2007092622A3 (en) Compositions and methods for treating bone
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
WO2007120626A3 (en) Uses and compositions for treatment of ankylosing spondylitis
EA201000559A1 (ru) Композиции и способы применения антител к склеростину
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
WO2008063213A3 (en) Uses and compositions for treatment of psoriatic arthritis
NO20092637L (no) Fremgangsmater for behandling
WO2008042231A3 (en) Compositions and methods for evaluating and treating heart failure
MX2010004219A (es) Agentes de enlace de cd19 y usos de los mismos.
MX2010009724A (es) Procedimientos de tratamiento del dolor inflamatorio-.
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
NO20091926L (no) Anti-Notch3-agonist-antistoffer og deres anvendelse ved behandlingen av Notch3-relaterte sykdommer
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
EP2373692A4 (en) IMMUNOGLOBULINE WITH DOUBLE VARIABLE DOMAIN AND ITS USE
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
PH12013500356A1 (en) Engineered anti-tslp antibody
WO2006091459A3 (en) Compositions and methods for treating vascular permeability
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
BRPI0712607A8 (pt) métodos de tratamento de acidente vascular cerebral
NO20071378L (no) Tiazolo-naftylsyrer.
NO20063856L (no) Behandling av psykoser med quetiapin-antipsykotiske midler
ATE434451T1 (de) Calciumphosphat materialien mit verbesserter osteoinduktivität
EP1959972A4 (en) PROCESS FOR TREATING OPEN INJURIES BY HYPOCHLOROUS ACID
DE602004012578D1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application